Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer by Jessica M Grunda et al.
Grunda et al. BMC Research Notes 2012, 5:248
http://www.biomedcentral.com/1756-0500/5/248RESEARCH ARTICLE Open AccessDifferential expression of breast cancer-associated
genes between stage- and age-matched tumor
specimens from African- and Caucasian-American
Women diagnosed with breast cancer
Jessica M Grunda1, Adam D Steg2, Qinghua He3, Mark R Steciuk4, Suzanne Byan-Parker4,
Martin R Johnson5 and William E Grizzle4*Abstract
Background: Recent studies suggest that the poorer breast cancer outcome observed in African-American women
(AAW) may, in part, result from underlying molecular factors. The purpose of this study was to investigate gene
expression differences between Caucasian-American women (CAW) and AAW that may contribute to this poorer
prognosis.
Methods: The expression of 84 genes involved in breast carcinoma prognosis, response to therapy, estrogen
signaling, and tumor aggressiveness was assessed in age- and stage-matched CAW and AAW paraffin-embedded
breast cancer specimens. The Wilcoxon–Mann–Whitney Test was used to identify genes with a significant difference
in expression between CAW and AAW. To determine if the differentially expressed genes could segregate between
the CAW and AAW, we performed semi-supervised principal component analysis (SSPCA).
Results: Twenty genes were differentially expressed between AAW and CAW. SSPCA incorporating these 20 genes
segregated AAW and CAW into two distinct groups. AAW were significantly (p< 0.05) more likely to display
aberrations in G1/S cell-cycle regulatory genes, decreased expression of cell-adhesion genes, and low to no
expression of ESR1, PGR, ERBB2 and estrogen pathway targets.
Conclusions: The gene expression differences identified between AAW and CAW may contribute to more
aggressive disease, resistance to therapy, enhanced metastatic potential and poor clinical outcome. These findings
support the hypothesis that breast cancer specimens collected from AAW display distinct gene expression
differences compared to similar tissues obtained from CAW. Additional population-based studies are necessary to
determine if these gene expression variations contribute to the highly aggressive and treatment-resistant breast
cancer phenotype frequently observed in AAW.
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Multiple studies have found distinct ethnic disparities in
breast cancer outcome between African-American
women (AAW) and Caucasian-American women
(CAW) in incidence rate, age-of-onset, mortality and
survival. Although the overall incidence rate for breast
cancer is higher in CAW compared to AAW, the age-
adjusted mortality rate for AAW (33/100,000) is signifi-
cantly higher than any other ethnic group examined,
including women of Caucasian descent [1]. In fact, AAW
at all breast cancer stages assessed (localized, regional &
distant) have a much lower 5-year survival rate (78%)
compared to CAW (90%) [2]. Although breast cancer
risk increases with age in all ethnicities, women of Afri-
can-American ancestry are more often diagnosed at a
much younger age, with 30–40% of AAW diagnosed with
breast cancer prior to 50 years of age, compared to just
20% for CAW [3]. This trend is even more striking con-
sidering AAW are diagnosed more frequently with
higher-grade tumors that are resistant to traditional ther-
apies [4]. The mechanisms underlying poorer outcome in
AAW diagnosed with breast cancer remains to be
elucidated.
Early studies suggested that the poorer outcome
observed for AAW diagnosed with breast cancer
resulted from disparities in social economic status (SES),
education level, access to health care, diet, religious
beliefs, and geographical location [5-9]. However, recent
research suggests that differences in clinical outcomes
likely arise from both societal and genetic factors. Sev-
eral large population-based meta-analyses report that
AAW display a significantly higher mortality rate than
when compared to any other ethnicity, even after
accounting for SES [10,11]. Additionally, even when Af-
rican and Caucasian-American women had equal access
to health care and/or underwent identical treatment
regimens, the disparity in patient outcome persisted. For
instance, two Department of Defense studies examining
treatment outcome in breast cancer patients found that
mortality rates were still significantly higher in AAW
versus CAW even though patients had equal access to
health care and underwent identical treatment regimens
[12,13]. Another study by Albain et al. investigating sur-
vival of breast cancer patients enrolled in randomized
clinical trials of the Southwest Oncology Group found
that overall survival rates for African American patients
were significantly poorer, even though patients received
the same treatment regimens and were controlled for
both prognostic factors and SES [14]. These studies col-
lectively support the hypothesis that while there are
sociological factors contributing to the higher mortality
rates seen in AAW, other causative factors exist.
A mounting body of evidence now suggests that
women of African-American ancestry may harbor agreater genetic predisposition for a more aggressive
breast cancer phenotype. Recent studies have demon-
strated that young, premenopausal women of African
American descent are more likely to display histological
characteristics depictive of the basal-like subtype of
breast cancer, known for its aggressive behavior and
poorer clinical outcome, compared to any other age
group of any other ethnic background examined [15,16].
Histologically, breast carcinomas from AAW more often
display pushing, non-infiltrative tumor margins, nuclear
pleomorphism, lymphocytic infiltrate, large primary
tumors, necrosis, lack of tubule formation, as well as
high mitotic indices and histological grade [15,17–21].
In addition, AAW are more likely to lack expression of
both the estrogen and progesterone receptors, and often
display the triple negative phenotype (ER-, PR-, HER2-),
thus precluding treatment with such targeted therapies
as tamoxifen, anastrozole, and Herceptin [17,20,22].
Women of African-American ethinicity are also more
likely to exhibit specific alterations in the levels of genes
involved in cell-cycle regulation and apoptosis, including
higher quantities of p16, p53, and cyclin E, and lower
levels of BCL-2, cyclin D1, and p27 [20,22]. In addition
to these ‘basal-like’ features, other studies have found
that AAW had a significantly higher prevalence of dele-
terious mutations in BRCA1 and BRCA2 compared with
CAW [23].
Many of these genetic differences may be associated
with differences in tumor grade and hormone receptor
status (ER and HER-2/neu), both of which have been
found to independently influence gene expression pro-
files. Although, a study recently published by Field et al.
determined that even when patient tissues were matched
on age, grade, and estrogen receptor status, significant
differences in gene expression profiles were still
observed [24]. The genes identified spanned a diverse
array of cellular functions including the proteasome sys-
tem, eye lens physiology, cell growth and differentiation,
and cellular immunity and inflammation [24]. While
these studies collectively provided insight into potential
biological factors contributing to the poor clinical out-
come of AAW, further studies are needed to clarify the
role of genetics in AAW breast cancer epidemiology.
The identification of potential gene expression differ-
ences driving the disparities in health outcome between
AAW and CAW is critical to improving the treatment
response and survival of these women as these molecu-
lar differences may impact breast cancer prevention,
screening practices, diagnostic testing and treatment
protocols. In this study we utilized a novel experimental
approach to investigate differences in gene expression
between AAW and CAW, independent from age or dis-
ease stage at diagnosis. Paraffin-embedded, age- and
stage-matched breast carcinoma samples from AAW
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specimens in tumor cell content (>80%). Gene expres-
sion analysis of genes previously implicated in breast
cancer prognosis, treatment response, estrogen signaling,
and tumor aggressiveness was performed using The
Human Breast Cancer and Estrogen Receptor Signaling
RT2 Profiler PCR Array from SABiosciences. Using the
Wilcoxon-Mann–Whitney Test we identified genes dis-
playing a significant difference in expression between
tumors obtained from AAW and CAW breast cancer
patients. These analyses identified a distinct molecular
profile in women of African-American descent, often
associated with the basal-like phenotype and previously
associated with resistance to therapy and poor clinical
outcome, supporting the hypothesis that AAW may have




Consent was obtained for all patients prior to start of
study. The use of human tissues was approved by and
conducted in accordance with the policies of the Institu-
tional Review Board at the University of Alabama at Bir-
mingham. The records of archival cases of breast cancer
from UAB Surgical Pathology were searched to identify
age (± 5 years) and stage (assessed by a pathologist)
matched cases of ductal carcinoma. The quality of the
available archival blocks from the matched cases was
then assessed through hematoxylin and eosin (H +E)
staining of newly cut sections from the original diagnos-
tic blocks. Sections were examined and selected for areas
of tumor that could be macrodissected into greater than
80% invasive cancer.
Analysis of receptor status
ER, PR and HER2 status were determined in the CAP/
CLIA accredited laboratory of University of Alabama at
Birmingham Hospital with the exception of one case.
Immunostaining of ER (Clone SP1) and PR (1 E2) was
performed using a semi-automated immunostainer
(Ventana, Model XT) and an Ultraview HPR Multitimer
approach. Tumors were considered positive if 1% or
greater of tumor cells stained. Percentage of staining as
well as intensity 1+ (weak) to 3+ (strong) was also
reported. The HER2/neu status was determined by CISH
using the Spot-Light Kit (Invitrogen), which is specific
for the HER2 gene locus on chromosome 17q11.2-21. A
minimum of 30 tumor cell nuclei were evaluated per pa-
tient. Criteria are as follows: ≥ 6 dots in the majority of
carcinoma cells is amplified, 4–6 is equivocal, and ≤ 4
dots is non-amplified. All evaluations are done by stand-
ard microscopy. Cases prior to 2005 were evaluated by
immunohistochemistry where 0 was negative if nostaining or membrane staining in less than 10% of tumor
cells, 1+ was negative if weak membrane staining in
greater that 10% of tumor cells, 2+ was positive if weak
to moderate complete membrane staining in greater
than 10% of tumor cells, and 3+ was positive if strong
complete membrane staining in greater than 10% of
tumor cells [25,26].
For the one case in which ER, PR, HER2/neu clinical
data was unavailable, immunostaining was performed in
Dr. William Grizzle’s research laboratory using ER alpha
(clone SP1), PR alpha and beta (clone PgR 636), and
HER2/neu (clone 3B5) and evaluated by a pathologist.
Sample preparation
Macrodissection
An H+E section was matched and orientated to the par-
affin block from which it was cut and areas of benign
tissue and non-invasive neoplasms were identified and
removed so that after macrodissection, the ductal carcin-
oma remaining in the block contained at least 80%
ductal carcinoma. The tumor areas were re-embedded
and new H+E sections were cut to confirm that the
ductal carcinoma was successfully enriched by the
macrodissection. Ten 10-μm sections were then cut for
RNA extraction.
RNA extraction
Paraffin tissue curls were deparaffinized as previously
described [27]. Total RNA isolation was then performed
using the Roche High Pure RNA Paraffin Kit (Roche
Diagnostics, Manheim, Germany) as per manufacturer’s
instructions. Total RNA was eluted in 30 μl of RNase-
free water and stored at −80°C until further analysis.
The concentration of all RNA samples was quantitated
through linear regression analysis of a standard curve
derived from known concentrations of normal breast
RNA. Ribosomal protein, large, P0 (RPLP0), which has
been previously validated by our laboratory [28], was
used as the housekeeping gene.
Reverse transcription
Complementary DNA was prepared using the RT2 First
Strand Kit (SABiosciences, Frederick, MD) as per manu-
facturer’s instructions. Approximately 0.5 μg of total
RNA from each sample was used for cDNA synthesis.
Analysis of samples by the RT2 profiler PCR array
The pre-designed Human Breast Cancer and Estrogen
Receptor Signaling RT2 Profiler PCR Array (SABios-
ciences) was utilized to simultaneously analyze 84 genes
related to breast cancer regulation and estrogen recep-
tor-dependent signal transduction in cDNA samples.
The housekeeping genes B2M, HPRT1, RPL13A,
GAPDH and ACTB are included on each Array. Each
Table 1 Unmatched characteristics in the study
population
Characteristic AAW (n= 11) CAW (n= 11)
Receptor Status
ER 6 55% 10 91%
PR 5 45% 7 64%
HER2 5 45% 7 64%
Tumor grade
Well 0 0% 2 18%
Moderate 2 18% 7 64%
Poor 9 82% 2 18%
Bloom and Richardson Score
I 0 0% 2 18%
II 2 18% 7 64%
III 9 82% 2 18%
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Master Mix (SABiosciences) and 25 μl of the mixture
was added to each well of the PCR Array using an eight-
channel pipettor. The plate was sealed and PCR amplifi-
cation was performed using an Applied Biosystems
Prism 7900HT sequence detection system. Thermal
cycler conditions were as follows: 2 minutes at 50°C, 10
minutes at 94.5°C, then 40 cycles of 30 seconds at 97°C
and 1 minute at 59.7°C. Delta cycle threshold (Delta CT)
and expression values were calculated using the com-
parative cycle threshold (CT) method as previously
described by our laboratory [27,29].
Statistical analysis
Fisher’s exact test
Fisher’s exact test is a statistical significance test used in
the analysis of contingency tables to calculate whether
there is a significant association between categorical
variables. It is employed when sample sizes are small so
the normal approximation and chi-square calculations
are not accurate [30].
Wilcoxon–Mann–Whitney test
In order to determine what genes were differentially
expressed between the CAW and AAW, we utilized the
Wilcoxon–Mann–Whitney test [31] using gene ΔCT
values. The Wilcoxon–Mann–Whitney test examines
the null hypothesis that gene expression levels in the
two groups (CAW and AAW) are independent samples
from identical continuous distributions with equal med-
ians, compared against the alternative that they do not
have equal medians. Each gene is evaluated independ-
ently to determine the statistical significance of the dif-
ference between the two-group medians. A p-value
of< 0.05 was considered statistically significance in this
study.
Semi-Supervised Principal Component Analysis (SSPCA)
To determine if the genes identified through the Wil-
coxon–Mann–Whitney test could visually segregate the
AAW and CAW into two distinct groups we performed
SSPCA [32,33]. In traditional PCA, all gene expression
values are used to identify combinations of genes that
separate samples into distinct groups. SSPCA has the
advantage of using only those genes previously asso-
ciated with clinical and/or demographic factors, and, in
this case, patient ethnicity, to segregate samples into
subgroups, thus allowing clear visualization of how gene
expression patterns segregate groups without interfering
background noise from genes that are not differentially
expressed. The Komogorov-Smirnov normality test was
applied to the identified principle components (PCs) to
ensure the data was approximately normally distributed
[34].Pearson correlation
To calculate the strength and direction of the linear as-
sociation between the expression of gene pairs across all
samples, and/or the AAW and CAW patient subpopula-
tions individually, we used Pearson’s Correlation. Pear-
son’s correlation assumes a Gaussian distribution of
gene expression values within sample sets (i.e. AAW
patients).
Hotelling’s T2 test
Hotelling’s T2 test is used in multivariate hypothesis
testing, which is a generalization of Student’s t test in
univariate hypothesis testing [35]. Given the case of p-
variate observations from two multivariate normally-
distributed populations with common covariance matrix,
Hotelling’s T2 statistic can be used to test the equality of
the vector of means associated with the two samples [35].
In this work, we apply Hotelling’s T2 test to examine the




Both age and disease stage at diagnosis are potential
factors influencing the poorer outcome observed in
women of African-American descent. To ensure that
any gene expression differences identified in this study
were not due to age or disease stage, we selected
age- and stage-matched paraffin-embedded samples of
ductal breast carcinoma samples from African- and
Caucasian-American women using archival records
stored at the University of Alabama at Birmingham.
From 80 matched archival specimens surveyed, 12
pairs were deemed of high enough quality for macro-
dissection and future study. All samples examined in
this study were collected through biopsy or tumor
Table 2 Human breast cancer and extrogen recptor RT2
profiler PCR array
Description Accession #:
Genes Associated with Breast Cancer Prognosis
Androgen receptor (AR) NM_000044
Antigen identified by monoclonal antibody
Ki-67 (MKI67)
NM_002417
B-cell CLL/lymphoma 2 (BCL2) NM_000633
BCL2-associated agonist of cell death (BAD) NM_004322
BCL2-associated athanogene (BAG1) NM_004323
Cadherin 1, type 1, E-cadherin (CDH1) NM_004360
Catenin (cadherin-associated protein), beta 1, (CTNNB1)NM_001904
Cathepsin B (CTSB) NM_001908
Clusterin (CLU) NM_001831
Collagen, type VI, alpha 1 (COL6A1) NM_001848
Cyclin A1 (CCNA1) NM_003914
Cyclin A2 (CCNA2) NM_001237
Cyclin D1 (CCND1) NM_053056
Cyclin E1 (CCNE1) NM_001238
Cyclin-dependent kinase inhibitor 1A (CDKN1A) NM_000389
Cyclin-dependent kinase inhibitor 1B (CDKN1B) NM_004064
Cyclin-dependent kinase inhibitor 2A (CDKN2A) NM_000077
Epidermal growth factor receptor (EGFR) NM_005228
Estrogen receptor 1 (ESR1) NM_000125
Estrogen receptor 2 (ESR2) NM_001437
Fas ligand (TNF superfamily, member 6) (FASLG) NM_000639
FOS-like antigen 1 (FOSL1) NM_005438
GATA binding protein 3 (GATA3) NM_002051
Gelsolin (GSN) NM_000177
Inhibitor of DNA binding 2 (ID2) NM_002166
Insulin-like growth factor binding protein 2 (IGFBP2) NM_000597
Integrin, alpha 6 (ITGA6) NM_000210
Integrin, beta 4 (ITGB4) NM_000213
Interleukin 2 receptor, alpha (IL2RA) NM_000417
Interleukin 6 (IL6) NM_000600
Interleukin 6 receptor (IL6R) NM_000565
Interleukin 6 signal transducer (IL6ST) NM_002184
Jun oncogene (JUN) NM_002228
Kallikrein-related peptidase 5 (KLK5) NM_012427
Keratin 19 (KRT19) NM_002276
Kruppel-like factor 5 (KLF5) NM_001730
Mitogen-activated protein kinase kinase 7 (MAP2K7) NM_145185
Mucin 1, cell surface associated (MUC1) NM_001018016
Nerve growth factor (NGF) NM_002506
Nerve growth factor receptor (NGFR) NM_002507
Prostaglandin-endoperoxide synthase 2 (PTGS2) NM_000963
TNF receptor superfamily, member 6 (FAS) NM_000043
Table 2 Human breast cancer and extrogen recptor RT2
profiler PCR array (Continued)
V-erb-b2 erythroblastic leukemia viral
oncogene homolog 2 (ERBB2)
NM_004448
Genes Associated with Estrogen Receptor Signaling
Non-metastatic cells 1 (NME1) NM_000269
Phosphatase and tensin homolog (PTEN) NM_000314
Plasminogen activator, urokinase (PLAU) NM_002658
Progesterone receptor (PGR) NM_000926
Serpin peptidase inhibitor, clade B, member 5
(SERPINB5)
NM_002639
Serpin peptidase inhibitor, clade E, member 1
(SERPINE1)
NM_000602
Thrombospondin 1 (THBS1) NM_003246
Topoisomerase (DNA) II alpha (TOP2A) NM_001067
Transforming growth factor, alpha (TGFA) NM_003236
Tumor protein p53 (TP53) NM_000546
Tyrosine kinase with immunoglobulin-like and
EGF-like domains 1 (TIE1)
NM_005424
Vascular endothelial growth factor A (VEGFA) NM_003376
Genes Associated with Response to Chemotherapy
Cathepsin D (CTSD) NM_001909
Complement component 3 (C3) NM_000064
Heat shock 27 kDa protein 1 (HSPB1) NM_001540
Keratin 18 (KRT18) NM_000224
Serpin peptidase inhibitor, member 3 (SERPINA3) NM_001085
Solute carrier family 7, member 5 (SLC7A5) NM_003486
Stanniocalcin 2 (STC2) NM_003714
Trefoil factor 1 (TFF1) NM_003225
Genes Associated with Breast Cancer
Diagnosis and Progression
BCL2-like 2 (BCL2L2) NM_004050
CD44 molecule (CD44) NM_000610
Claudin 7 (CLDN7) NM_001307
Cytochrome P450, family 19, subfamily A,
polypeptide (CYP19A1)
NM_000103
Deleted in liver cancer 1 (DLC1) NM_006094
Fibroblast growth factor 1 (FGF1) NM_000800
Fibronectin leucine rich transmembrane
protein 1 (FLRT1)
NM_013280
Gamma-aminobutyric acid (GABA) A receptor,
pi (GABRP)
NM_014211
GNAS complex locus (GNAS) NM_080425
High-mobility group box 1 (HMGB1) NM_002128
Metallothionein 3 (MT3) NM_005954
Nuclear transcription factor Y, beta (NFYB) NM_006166
Pregnancy-associated plasma protein A,
pappalysin 1 (PAPPA)
NM_002581
Ras-related C3 botulinum toxin substrate 2 (RAC2) NM_002872
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Table 2 Human breast cancer and extrogen recptor RT2
profiler PCR array (Continued)
Ribosomal protein L27 (RPL27) NM_000988
Secretoglobin, family 1D, member 2 (SCGB1D2) NM_006551
Secretoglobin, family 2A, member 1 (SCGB2A1) NM_002407
Small proline-rich protein 1B (SPRR1B) NM_003125
Thrombospondin 2 (THBS2) NM_003247
Tumor necrosis factor, alpha-induced protein 2
(TNFAIP2)
NM_006291




Actin, beta (ACTB) NM_001101
Beta-2-microglobulin (B2M) NM_004048
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) NM_002046
Hypoxanthine phosphoribosyltransferase 1 (HPRT1) NM_000194
Ribosomal protein L13a (RPL13A) NM_012423
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other therapies. Patient treatment was not significantly
different between AAW and CAW for the 24
patients, and consisted mainly of lumpectomy, total
mastectomy, radiotherapy, tamoxifen, and arimidex.
Due to the short amount of elapsed time between ini-
tial patient diagnosis and study analysis, associations
between clinical parameters (race, age, disease stage,
and treatment) and patient survival could not be
determined.
As illustrated in Table 1, AAW were more likely to be
negative for ER, PR, and HER2, however this observa-
tion was not significant, perhaps owing to small number
of samples examined in this study. In contrast, patient
ethnicity was significantly associated with tumor grade
(p = 0.0131) with AAW patients more often displaying a
higher tumor Grade (Table 1).
Gene expression differences between AAW and CAW
Previous studies suggested that AAW women might
have a genetic predisposition for a more aggressive
breast cancer phenotype. To investigate this possibility
further, we examined differences between AAW and
CAW patient samples in the expression of 84 genes pre-
viously implicated in breast cancer aggressiveness, estro-
gen receptor signaling, resistance to chemotherapy, and
patient prognosis using the Human Breast Cancer and
Estrogen Receptor Signaling RT2 Profiler PCR Array
from SABiosciences (Table 2). Based on gene Delta CT
values, the Wilcoxon–Mann–Whitney test determined
that 20 of the 84 genes examined were significantly dif-
ferentially expressed (p≤ 0.05) between the AAW and
CAW patients, with a greater than 2-fold change in ex-
pression (Table 3; Figure 1). Of these 20 genes, onlyCDKN2A displayed increased expression in women of
African-American descent.
We then visualized the ability of the 20 differentially
expressed genes to segregate the AAW and CAW
patients into distinct molecular subgroups. SSPCA was
performed by applying only the 20 genes identified by
the Wilcoxon-Mann–Whitney test in principal compo-
nent analysis. Application of the Kolmogorov-Smirnov
normality test to the first three identified PCs deter-
mined that all three principle components (PCs) had an
approximate normal distribution (p< 0.05) across both
patient ethnicities. Based on the multivariate Hotelling
T-Squared test, as would be expected the 20-gene com-
bination significantly separated the breast cancer
patients into two distinct subgroups (Figure 2) using
PC1 (p< 0.001), PC1 and PC2 (p< 0.001), or the first
three PCs (p< 0.001).
A comprehensive review of the literature determined
that of the 20 differentially expressed genes, 70% (AR,
BCL2, CCND1, ESR1, GATA3, IGFBP2, IL6ST, KRT19,
MUC1, PGR, SERPINE1, HSPB1, SERPINA3, and STC2)
have been previously associated with estrogen signaling
and/or estrogen receptor 1 expression. To determine if
similar associations with estrogen signaling could be
detected in this study, Pearson’s correlation was used to
determine the strength and direction of any underlying
relationships with ESR1 expression. Of the above listed
genes, ESR1 was positively associated with the expres-
sion of BCL2, GATA3, IL6ST, MUC1, SERPINE1, AR,
and HSPB1 expressions in women of African-American
descent, with BCL2 displaying the strongest association
(Table 3). In contrast, only the expression of KRT19 and
CCND1 were correlated with ESR1 expression in the
Caucasian population (Table 4).
In addition to estrogen signaling genes, 4 of the 20
identified genes have been implicated in resistance to
targeted therapies (ERBB2, ESR1, PGR, and AR). Previ-
ous studies have reported that tumor specimens from
women of African-American heritage are significantly
more likely to lack expression of the hormone receptors
ESR1, PGR, and AR, compared to other ethnicities. In
the current study we found significantly lower expres-
sion of these receptors (6.7-fold) in the AAW compared
to CAW patients (Table 3) for PGR (58%; 17%), and
ESR1 (58%; 17%) respectively. In addition, a larger per-
centage of AAW than CAW patients had no measurable
expression of the PGR (33%; 8%) and ESR1 (50%; 8%)
genes respectively. AAW patients were also less likely to
express ERBB2 (42%; 8%).
In addition to estrogen signaling and resistance to
therapy, 7 of the identified genes have been previously
associated with cell cycle regulation (CCND1, CDKN1A,
CDKN1B, and CDKN2A) and breast cancer aggressive-
ness (CLDN7 and DLC1) (Table 3).
Table 3 Breast cancer genes differentially expressed between CAW and AAW patient populations
Gene Description CAWa AAWb CAW/AAWc P-valued
Genes Associated with Breast Cancer Prognosis
AR Androgen receptor 0.99 0.38 2.60 0.002
BCL2 B-cell CLL/lymphoma 2 0.65 0.20 3.28 0.010
CCND1 Cyclin D1 0.78 0.28 2.75 0.030
CDKN1A Cyclin-dependent kinase inhibitor 1A 2.07 0.90 2.29 0.002
CDKN1B Cyclin-dependent kinase inhibitor 1B 1.68 0.74 2.26 0.001
CDKN2A Cyclin-dependent kinase inhibitor 2A 1.35 3.55 0.38 0.046
ERBB2 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 1.61 0.63 2.56 0.012
ESR1 Estrogen receptor 1 1.79 0.46 3.91 0.023
GATA3 GATA binding protein 3 1.57 0.17 9.33 0.001
IGFBP2 Insulin-like growth factor binding protein 2, 36 kDa 1.53 0.73 2.11 0.005
IL6ST Interleukin 6 signal transducer 1.15 0.44 2.64 0.005
KRT19 Keratin 19 1.44 0.71 2.03 0.012
MUC1 Mucin 1, cell surface associated 1.77 0.36 4.94 0.004
PGR Progesterone receptor 0.77 0.33 2.34 0.012
SERPINE1 Serpin peptidase inhibitor, clade E, member 1 7.59 3.18 2.38 0.014
Genes Associated with Response to Chemotherapy
HSPB1 Heat shock 27 kDa protein 1 0.98 0.46 2.14 0.003
SERPINA3 Serpin peptidase inhibitor, clade A, member 3 0.43 0.20 2.16 0.017
STC2 Stanniocalcin 2 0.79 0.38 2.05 0.019
Genes Associated with Breast Cancer Progression
CLDN7 Claudin 7 1.76 0.66 2.67 0.006
DLC1 Deleted in liver cancer 1 4.27 0.94 4.52 0.023
a Average Gene Expression of Caucasion-American Women (CAW, n = 12).
b Average Gene Expression of African-Amercian Women (AAW, n = 12).
c Gene Expression Fold Change Relative to the Average Gene Expression of AAW.
d P-values calculated using the Wilcoxin Rank Sum Test.
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Women of African-American descent are diagnosed with
breast cancer at a younger age and clinical stage than
their Caucasian counterparts. In addition, although
CAW have a higher incidence of breast cancer, AAW
have poorer survival rates. While multiple studies have
shown that these disparities in health outcomes are, in
part, due to such societal factors as social economic sta-
tus, access to appropriate health care, diet and religious
beliefs, population-based studies showed that differences
in patient diagnosis and survival remained even after
taking such factors into account, suggesting biological
underpinnings in race may be responsible. Identification
of genetic contributors that may be driving the racial dif-
ferences in clinical outcome is critical as such factors
may alter preventative medicine, cancer screening prac-
tices, and therapeutic guidelines. The aim of the current
study was to gain a more in-depth understanding of
gene expression differences between AAW and CAW
breast cancer patients that may contribute to the poorer
outcome of AAW patients.Interestingly, even though patients were matched on
both age and stage at diagnosis, tumor tissues from
women of African decent were significantly more likely
to be of higher grade. Although AAW tumors were also
more likely to display the triple negative (ER-, PR-,
HER2-) phenotype, these observations did not reach
statistical significance. Higher grade and a triple negative
phenotype are known negative predictors of breast can-
cer prognosis. Thus, these findings are in agreement
with past studies and support that AAW have a molecu-
lar predisposition for a more aggressive breast cancer
phenotype.
In the current study the expression of 84 genes
(Table 2) previously implicated in breast cancer aggres-
siveness, estrogen receptor signaling, resistance to
chemotherapy, and patient prognosis were examined in
formalin-fixed, paraffin-embedded (FFPE) tissues
obtained from age- and stage-matched AAW and CAW
patients. Gene expression analysis of archival tissues has
traditionally been problematic due to nucleotide degrad-
ation resulting from tissue processing. However,
Figure 1 Heat map illustrating differences in the expression of
20 breast cancer-associated genes between AAW and CAW
breast cancer patients.
Figure 2 Semi-Supervised Principal Component Analysis
significantly (p< 0.005) segregated the AAW and CAW breast
cancer patients into two distinct groups based on
combinations of the first three principal components (PCs).
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lation from and expression analysis of FFPE tissues
[36,37]. In fact, several studies specifically comparing
gene expression profiles from matched snap-flash frozen
and FFPE tissues demonstrated significant concordance
(r = 0.92, P< 0.0001) [29,38], opening the use of archival
tissues for gene expression analysis.
The current study identified 20 genes that had a sig-
nificant and greater than 2-fold change in expression be-
tween AAW and CAW patients using the Wilcoxon-
Mann–Whitney test (Table 3). As illustrated in Figure 1,
virtually all of the genes identified displayed increased
expression in Caucasian compared to African-American
women. Only CDKN1A displayed a significantly higher
expression in AAW. To determine if the differential
expression of these genes could discriminate between
African-American and Caucasian patients, we performed
SSPCA. SSPCA is advantageous over general principal
component analysis in that, by only using those genes
associated with ethnic background, patient clustering can
be visualized without background noise resulting from
genes that are not differentially expressed. This analysis
determined that the AAW and CAW breast cancer
patients could be visually clustered based only on the ex-
pression of these 20 genes using combinations of principal
component PC1, PC2, and PC3 (Figure 2, p< 0.001 for all
PC combinations).
In support of previous studies examining molecular
differences between African-American and Caucasian-
American women, our study suggests that AAW have a
gene expression-based predisposition for a moreaggressive and treatment resistant tumor phenotype than
CAW. The 20 differentially expressed genes identified
(Table 3) have been implicated in cell cycle regulation,
response to therapy, estrogen signaling and breast cancer
aggressiveness. Abnormalities in the levels of G1/S phase
cell-cycle regulatory proteins have been previously asso-
ciated with breast cancer prognosis and response to
therapy [39-44]. In our study the expression of CCND1,
CDKN1A and CDKN1B was significantly elevated, while
CDKN2A was significantly lower, in Caucasian-American
compared to African-American patients. CCND1 (Cyclin
D) drives the G1/S phase transition through binding with
cyclin dependent kinase 4 (CDK4) and cyclin dependent
kinase 6 (CDK6), which then phosphorylates retino-
blastoma (pRb), inducing downstream Cyclin E tran-
scription [45]. In contrast CDKN1A (p21), CDKN1B
(p27), and CDKN2A (p16) are cyclin dependent kinase
inhibitor proteins (CDK inhibitors) involved in cell cycle
arrest through inhibition of CDK4, CDK6, and cyclin
dependent kinase 2 (CDK2) [45]. As a whole, the lower
expression of CCND1, CDKN1A and CDKN1B, and
higher expression of CDKN2A in AAW versus CAW
patients would hypothetically result in decreased cellu-
lar proliferation in AAW tumor specimens, yet AAW
patient tissues had a statistically significant higher grade
than CAW specimens in this study. Interestingly, other
studies have also observed this same contradiction [20],
and in fact, have noted a distinct inverse relationship
between cyclin D1 [20,46,47] and p16 [20,48,49] levels
with poorer clinical outcome, a more aggressive cancer
phenotype, and resistance to multiple chemotherapeutic
agents. The collective findings of our and these studies
suggest that deregulation of cell-cycle G1 regulatory
Table 4 Genes previously associated with estrogen
signalling
CAW AAW
Gene r P - Value r P - Value
BCL2 NS NS 0.95 <0.001
CCND1 0.65 0.0228 NS NS
GATA3 NS NS 0.76 0.0043
IGFBP2 NS NS NS NS
IL6ST NS NS 0.85 0.0043
KRT19 0.76 0.0041 NS NS
MUC1 NS NS 0.84 0.0006
SERPINE1 NS NS 0.86 0.004
AR NS NS 0.80 0.0017
HSPB1 NS NS 0.82 0.001
SERPINA3 NS NS NS NS
STC2 NS NS NS NS
NS Not Significant.
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tage and may contribute to the poorer outcome of this
ethnic group.
In addition to differences in cell-cycle regulatory genes,
we also noted distinct differences in the expression of
genes previously implicated in treatment response be-
tween AAW and CAW patient tumor specimens. As
clearly illustrated in Figure 2, AAW patients had signifi-
cantly lower (P< 0.05) expression of ESR1 (ER), PGR
(PR), and ERBB2 (HER-2), compared to CAW patients
with a greater percentage of AAW patients exhibiting no
detectable expression of ESR1 (8% vs. 50%) or PGR (8%
vs. 33%). A similar trend was observed in the tumoral
protein receptor status for ER, PR, and HER2 (Table 1).
These data add to the growing body of evidence that
women of African-American descent are statistically
more likely to be estrogen and progesterone receptor-
negative [17,50-53]. ER+ and PR+ tumor status is typ-
ically associated with increased survival and enhanced
response to hormonal therapy. In contrast, lack of estro-
gen and progesterone receptor expression has been asso-
ciated with a more aggressive phenotype and worse
clinical outcome, as lack of estrogen or progesterone re-
ceptor status precludes treatment with tamoxifen or tras-
tuzumab [50,51]. Unlike the racial differences observed
for ESR1 and PGR, no such association has been
described for ERBB2. In two separate multiethnic popu-
lation-based studies conducted by Elledge et al. [52] and
Porter et al. [20], HER-2 levels were found to be similar
between all ethnic groups examined. However, the pro-
tein expression of HER-2 was assessed through immuno-
histochemistry in both of these studies, and thus
differences in findings may reflect a dissociation between
protein and mRNA levels of HER-2/ERRB2. Whileelevated ERRB2 expression has been associated with
increased disease recurrence, metastasis, and shorter sur-
vival, enhanced survival is also observed for these
patients when treated with HER-2 targeted therapies
such as Herceptin [54,55] and Tykerb [54,56]. These
results suggest AAW may harbor gene expression profile
differences that increase tumor resistance to current tar-
geted hormone and HER2 therapies. Collectively, this
data supports that there are inherent gene expression dif-
ferences in ESR1, PGR, and ERBB2 between women of
African and Caucasian-American decent that potentially
contributes to the triple negative phenotype (ER-, PR-,
and HER2-) and poorer outcome often observed for
AAW.
Interestingly, 70% of the genes differentially expressed
between African-American and Caucasian-American
women in our study have been implicated in estrogen
signaling, including AR, BCL2, CCND1, ESR1, GATA3,
IGFBP2, IL6ST, KRT19, MUC1, PGR, SERPINE1, HSPB1,
SERPINA3, and STC2, all of which displayed decreased
expression in AAW compared to CAW patients
(Table 4). The expression of AR [57,58], BCL2 [57-59],
CCND1 [57,58,60], GATA3 [57,58,61,62], IL6ST [57,58],
MUC1 [58,63,64], PGR [57,65], SERPINE1 [66,67],
HSPB1 [58,68,69] and STC2 [57,58,69,70] have been
positively associated with ESR1 expression and/or upre-
gulated by ESR1. Other studies have found estrogen can
directly upregulate transcription of AR [57], GATA3
[57], IGFBP2 [71,72], KRT19 [73], and MUC1 [64], PGR
[57,74,75], SERPINE1 [76], HSPB1 [77-79], SERPINA3
[80,81], SERPINE1 [76], and STC2 [57,69,70]. In support
of these studies, we also found that the expression of
AR, BCL2, GATA3, IL6ST, MUC1, PGR, SERPINE1, and
HSPB1, were significantly associated with ESR1 expres-
sion in AAW; although, only KRT19 and CCND1 were
positively correlated with ESR1 levels in American
women of Caucasian descent. Interestingly, lower levels
of BCL2 [59,82,83], CCND1 [46,84], GATA3 [62,85,86],
IL6ST [87], KRT19 [88], MUC1 [63,64,89], PGR [65,90],
SERPINE1 [66], SERPINA3 [69], STC2 [91], while higher
levels of AR [65,92], SERPINA3 [69], and STC2 [69] have
been associated with enhanced response to hormone
therapy in sex steroid positive tumors. These results sug-
gest that women of African-American ethnicity are more
prone to displaying negative or low expression of ESR1
and its associated estrogen response genes, which have
been correlated with resistance to hormone therapy and
worse clinical outcome.
In addition to genes involved in cell cycle, treatment
response, and estrogen signaling, we also determined
that the cell adhesion-related genes CLDN7 and DLC1
were significantly decreased in the AAW patients
(Table 3, Figure 1). CLDN7 is a member of the claudin
family of transmembrane proteins, which are critical
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[93,94], necessary for cell-cell adhesion. Studies suggest
that loss of tight junctions from down-regulation of
claudins in various cancers, results in loss of cohesion,
increased invasiveness, and cell dedifferentiation [95]. In
support of these findings, loss or decreased expression
of CLDN7, which is expressed constitutively during
mammary epithelium development [96], has been sig-
nificantly associated with higher histological grade, loss
of cellular cohesion, and increased metastasis in breast
carcinoma [97,98]. In light of this data, CLDN7 has been
proposed as a breast cancer tumor-suppressor gene. Like
CLDN7, DLC1 is has been considered a tumor suppres-
sor gene involved in the regulation of the actin cytoskel-
eton, cell polarity, inter-cell focal adhesion, cell
migration, and apoptosis [99-101] through negative regu-
lation of Rho signaling pathways [99]. DLC1 is expressed
in multiple tissues including the brain, heart, kidney,
liver, lung, skin, spleen, and testis [102]. Studies have
found that the mRNA levels of DLC1 are diminished in
various cancers [103], including breast, through loss of
heterozygosity or heterozygous gene deletions [104]. Fur-
thermore, several studies investigating the role of DLC1
in breast cancer found that forced expression of DLC-1
in DLC-1 negative breast cancer cell lines resulted in
growth inhibition, reduction in colony formation, and
abolishment of in vivo tumorigenicity [103,105], whereas
downregulation of DLC1 expression enhanced cell motil-
ity and chemotactic behavior [106]. These studies suggest
that loss or reduced expression of CLDN7 and DLC1, as
was observed in tumor specimens from AAW, may lead
to increased cell motility, migration, metastasis and de-
differentiation, all of which may contribute to the worse
clinical prognosis observed for AAW.
The large number of gene expression differences
observed in this study between AAW and CAW patients
supports that women of African-American decent may
harbor differences in gene expression profiles that pre-
dispose them to increased tumor grade, a triple negative
(ER-, PR-, HER2-) phenotype, and worse clinical disease
outcome. Future studies are needed to determine if these
gene expression profiles are grade and receptor status
specific or represent other attributing factors to AAW
poorer prognosis.
Conclusions
The main objective of this study was to identify gene ex-
pression differences between AAW and CAW that may
contribute to the poor clinical outcome observed for
women of African-American descent. While the small
sample size examined in this study is a limiting factor,
the use of only age- and stage-matched tumor specimens
strengthens findings from this study. This study demon-
strated that tumor specimens from AAW weresignificantly more likely to display aberrations in G1/S
cell-cycle regulatory genes, lack or exhibit low expres-
sion of ESR1, PGR, and ERBB2 with a decrease in estro-
gen signaling pathway targets, and display a decrease in
the expression of cell-adhesion genes. These factors have
been collectively linked with a more aggressive cancer
phenotype, resistance to multiple chemotherapeutic
agents, enhanced metastatic potential, and poorer clin-
ical outcome, further supporting the hypothesis that
women of African-American ancestry have ethnic differ-
ences in gene expression patterns that predisposes them
to a highly aggressive and treatment-resistant breast can-
cer phenotype.
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